Advanced cardiac life support for the new millennium

Journal of Cardiovascular Nursing

Volumn 16, Issue 3, 2002, Pages 9-23

  Housholder Hughes, Susan D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Advance cardiac life support; Cardiac arrest; Cardiopulmonary resuscitation; Emergency cardiac care; Emergency medical system; Resuscitation

Indexed keywords

ACUTE DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; HEART ARRHYTHMIA; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; RESUSCITATION; REVIEW; STANDARD; UNITED STATES;

ACUTE DISEASE; ADVANCED CARDIAC LIFE SUPPORT; AMERICAN HEART ASSOCIATION; ARRHYTHMIA; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; HUMANS; PRACTICE GUIDELINES; UNITED STATES;

EID: 20244375963     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200204000-00003     Document Type: Article

References (70)

1. American Heart Association. Standards for cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC). JAMA. 1994;227:837-867.
2. Carveth S, Burnap T, Bechtel J. Training in advanced cardiac life support. JAMA. 1976;235:2311-2315.
3. American Heart Association. Standards and guidelines for cardiopulmonary and emergency cardiac care, IV: advanced cardiac life support. JAMA. 1980;244:479-494.
4. American Heart Association. Standards and guidelines for cardiopulmonary and emergency cardiac care, I: introduction. JAMA. 1980;244:453-460.
5. American Heart Association. Standards and guidelines for cardiopulmonary resuscitation and emergency cardiac care, III: adult advanced cardiac life support. JAMA. 1986;255:2933-2954.
6. American Heart Association. Standards and guidelines for cardiopulmonary resuscitation and emergency cardiac care, I: introduction. JAMA. 1986;255:2905-2914.
7. American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care, III: adult advanced cardiac life support. JAMA. 1992;268:2199-2241.
8. American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care, I: introduction. JAMA. 1992;268:2172-2183.
9. American Heart Association. Advanced Cardiac Life Support. Dallas, TX: American Heart Association; 1997.
10. American Heart Association & International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care: an international consensus on science. Circulation. 2000;102(suppl):I-1-I-384.
11. American Heart Association. 2000 Handbook of Emergency Cardiovascular Care for Healthcare Providers. Dallas, TX: American Heart Association; 2000.
12. American Heart Association. Textbook of Advanced Cardiac Life Support. Dallas, TX: American Heart Association; 1994.
13. American Heart Association. ACLS Provider Manual. Dallas, TX: American Heart Association; 2001.
14. Larson MP, Eisenberg MS, Cummins RO, et al. Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann Emerg Med. 1993;22:1652-1658.
15. White RD, Hankins DG, Bugliosi TF. Early defibrillation by police: initial experience with measurement of critical time intervals and patients outcome. Ann Emerg Med. 1994;23:1009-1013.
16. White RD, Hankins DG, Bugliosi TF. Seven years' experience with early defibrillation by police and paramedics in an emergency medical services system. Resuscitation. 1998;39:145-151.
17. Davis EA, Mosesso VN Jr. Performance of police first responders in utilizing automated external defibrillation on victims of sudden cardiac arrest. Prehosp Emerg Care. 1998;2:101-107.
18. O'Roarke MF, Donaldson E, Geddes JS. An airline cardiac arrest program. Circulation. 1997;96: 2849-2853.
19. Wolbrink A, Borrillo D. Airline use of automatic external defibrillators: shocking developments. Aviat Space Environ Med. 1999;70:87-88.
20. Heere JM, Higgins SL, Epstein AE, et al. A comparison of biphasic and monophasic shocks for external defibrillation of humans. Circulation. 1998;98(suppl 1):1-173.
21. Tang W, Weil MH, Sun S, et al. The effects of biphasic and conventional monophasic defibrillation on post resuscitation myocardial function. J Am Coll Cardiol. 1999;34:815-822.
22. Rivers E, Wortsman J, Rady M, et al. The effect of total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variable in the postresuscitation period. Chest. 1994;106:1145-1150.
23. Behringer W, Kittler H, Sterz F, et al. Cumulative epinephrine dose during cardiopulmonary resuscitation and neurologic outcome. Ann Intern Med. 1998;129:450-456.
24. Lindner KH, Prengel AW, Strohmenger HU, et al. Vasopressin administration in refractory cardiac arrest. Ann Intern Med. 1996;124:1061-1064.
25. Chugh S, Lurie K, Lindner K. Pressor with promise: using vasopressin in cardiopulmonary arrest. Circulation. 1997;96:2453-2454.
26. Gonzalez E, Kannewurf B, Ornato J. Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. Resuscitation. 1998;39:33-42.
27. Connolly S. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025-2034.
28. Farre J, Romero J, Rubio J, et al. Amiodarone and primary prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol. 1999;83:55D-63D.
29. Naccarelli G, Wolbrette D, Dell'Orfano J, et al. Amiodarone: what have we learned from clinical trials? Clin Cardiol. 2000;23:73-82.
30. Kowey P, Marinchak R, Rials S, et al. Intravenous amiodarone. J Am Coll Cardiol. 1997;29:1190-1198.
31. Kudenchuk P, Cobb L, Copass M, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. JAMA. 1999;341:871-878.
32. Heartwire. Amiodarone More Effective than Lidocaine in ACLS for Shock-Resistant Ventricular Fibrillation. Available at:. Accessed May 7, 2001.
33. Brzozowski L. Wide QRS complex tachycardia. AACN Clin Iss Crit Care Nurs. 1992;3:173-179.
34. Marriott HJL, Conover MB. Advanced Concepts in Arrhythmias. 2nd ed. St Louis, Mo: Mosby; 1989.
35. Marriott, HFL. Practical Electrocardiography. 8th ed. Baltimore, Md: Williams & Wilkins; 1998.
36. 6 in distinguishing aberrant supraventricular from ventricular ectopic beats. PACE. 1991;14:1375-1383.
37. Wellens H, Bar F, Lie K. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med. 1978;64:27-33.
38. Owen A. How to distinguish wide-complex tachycardias. Crit Care Choices. 1996;5-10.
39. Opie L. Drugs for the Heart. 4th ed. Philadelphia, Pa: Saunders; 1997.
40. Del Monte L, Gamrath B. Noninvasive Pacing: What You Should Know. Redmond, WA: Physio-Control; 1996.
41. Eichhorn D, Meyers T, Guzzetta C, et al. Family presence during invasive procedures and resuscitation: hearing the voice of the patient. Am J Nurs. 2001;101:48-55.
42. Hanson C, Strawser D. Family presence during cardiopulmonary resuscitation: Foote Hospital emergency department's nine-year perspective. J Emerg Nurs. 1992;18:104-106.
43. Meyers T, Eichhorn D, Guzzetta C. Do families want to be present during CPR? A retrospective survey. J Emerg Nurs. 1998;24:400-405.
44. Boyd R. Witnessed resuscitation by relatives. Resuscitation. 2000;43:171-176.
45. American Heart Association. Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.
46. Vance D. Treating acute ischemic stroke with intravenous alteplase. Crit Care Nur. 2001;21:25-34.
47. Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first ever and recurrent) stroke. Stroke. 1999;30:2523-2528.
48. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
49. Adams H, delZoppo G, von Kummer R. Management of Stroke: A Practical Guide for the Prevention, Evaluation and Treatment of Acute Stroke. Caddo, OK: Professional Communications; 1998.
50. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
51. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety and efficacy in the first year of clinical practice. Stroke. 1998;29:8-22.
52. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
53. Gallan S, Asberg A, Indredavick B, et al. A decision analysis of thrombolytic therapy compared with standard therapy in acute ischemic stroke. J Intern Med. 1999;246:549-559.
54. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150.
55. Alberts MJ, Chaturvedi S, Graham G, et al. Acute stroke teams: results of a national survey. National Acute Stroke Team Group. Stroke. 1998;29:2318-2320.
56. Doering L. Pathophysiology of acute coronary syndromes leading to acute myocardial infarction. J Cardiovasc Nurs. 1999;13:1-20.
57. Shah PK, Moreno P, Falk E. Pathopysiology of plaque rupture. J Vasc Med Biol. 1995;5:244-258.
58. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q wave myocardial infarction. Circulation. 1998;97:1195-1206.
59. Coller B, Anderson K, Weisman H. New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thrombosis Haemostasis. 1995;74:302-308.
60. Topol E, Califf R, Weisman, H, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
61. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
62. The Platelet Glycopotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;338:436-443.
63. The ESPRIT Trial: A randomized controlled trial. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2001;285:2468-2473.
64. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
65. CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study Lancet. 1997;349:1429-1435.
66. Tcheng J. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into perspective. Am J Cardiol. 1996;789(suppl 3A):35-40.
67. Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Am J Cardiol. 1998;82:19-24.
68. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction; results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-1601.
69. Fragmin and fast revascularization during instability in coronary artery disease investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet. 1999;354;701-707.
70. Zed P, Tisdale J, Borzak S. Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med. 1999;159:1849-1857.